Compare AGRZ & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGRZ | ICU |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 9.1M |
| IPO Year | N/A | N/A |
| Metric | AGRZ | ICU |
|---|---|---|
| Price | $0.33 | $3.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 134.0K | 70.7K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $53.00 |
| Revenue Next Year | N/A | $50.00 |
| P/E Ratio | $4.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $0.22 |
| 52 Week High | $7.20 | $5.10 |
| Indicator | AGRZ | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 44.95 |
| Support Level | $0.33 | $3.72 |
| Resistance Level | $0.61 | $4.96 |
| Average True Range (ATR) | 0.04 | 0.39 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 23.43 | 6.16 |
Agroz Inc is a vertically integrated agricultural technology (AgTech) company focused on designing, innovating, developing, building, operating and managing large, commercial-scale, industrial-grade indoor CEA vertical farms using CEA practices. Its mission is to improve food safety, food security, and sustainability for society by creating a reliable, accessible food supply through its AgTech products and services. CEA vertical farming is an agricultural method involving crop cultivation through vertically stacked layers in a controlled indoor environment. CEA practices are defined by growing produce in spaces where environmental conditions can be controlled and manipulated to match the needs of specific plants.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.